Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly anticipates full-year worldwide revenue of approximately $45.0 billion in 2024, reflecting a 32% year-over-year growth but falling slightly below the consensus estimate of $45.49 billion.

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.